Understanding how B cells develop into antibody-producing cells
Epigenetic regulation of early B cell differentiation
['FUNDING_R01'] · EMORY UNIVERSITY · NIH-11114046
This study is looking at how certain immune cells called B cells decide to become antibody-making cells, which help fight infections, and it aims to find ways to better stimulate these cells for creating effective vaccines and treatments for diseases like COVID-19.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | EMORY UNIVERSITY (nih funded) |
| Locations | 1 site (ATLANTA, UNITED STATES) |
| Trial ID | NIH-11114046 on ClinicalTrials.gov |
What this research studies
This research investigates the processes that lead to the differentiation of B cells into antibody-secreting cells, which are crucial for the immune response against infections. It focuses on the transcriptional and epigenetic mechanisms that guide B cells in making decisions about their fate, whether to become antibody-secreting cells or memory B cells. By studying these processes in detail, the research aims to uncover how B cells can be effectively stimulated to produce antibodies, which is vital for developing vaccines and therapies for diseases like COVID-19. The research utilizes in vivo models to observe B cell behavior and the unique epigenetic changes that occur during their differentiation.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with autoimmune conditions or those interested in understanding their immune response to infections.
Not a fit: Patients with established B cell malignancies or those not experiencing immune-related issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved vaccines and therapies that enhance the body's ability to fight infections.
How similar studies have performed: Previous research has shown promising results in understanding B cell differentiation and its implications for vaccine development, indicating that this approach is building on established knowledge.
Where this research is happening
ATLANTA, UNITED STATES
- EMORY UNIVERSITY — ATLANTA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BOSS, JEREMY M. — EMORY UNIVERSITY
- Study coordinator: BOSS, JEREMY M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.